Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory future unclear after mixed EGFR+ NSCLC results.

Eli Lilly reported the first Phase 3 data for its oral GLP-1 orforglipron Thursday morning, saying the drug succeeded in a type 2 diabetes trial. The drug hit the primary ...

Pfizer discontinues obesity pill danuglipron after potential drug-induced liver injury in trial patient; company has GIP receptor antagonist PF-07976016 in Phase 2a testing.

Zealand Pharma partners with Roche on obesity drug petrelintide in $5.3B deal. Roche pays $1.4B upfront, plans combo studies with CT-388. Companies to split revenues in US/Europe.

Arvinas/Pfizer's vepdegestrant shows efficacy in mutated breast cancer patients but not in broader population, failing to outperform similar drugs, Phase 3 VERITAC-2 trial show

A survey of 77 biotech executives reveals concerns about FDA changes following Donald Trump's reelection. Martin Makary's nomination as FDA chief has eased some worries, while Robert F. Kennedy Jr.'s ...